



SLC01B1 c.521T>C RealFast™ Assay

The easy way to determine the response to statin therapy and thus avoid dose-dependent adverse events

Lower risk for simvastatin induced myopathy through established innovations in diagnostics

Statins (e.g. simvastatin) are most widely prescribed as treatment for low-density lipoprotein cholesterol reduction and control. In general statins are considered as safe and well tolerated drugs. However, some patients experience severe side effects and opt to discontinue therapy. The clinical spectrum may range from frequent pain with or without evidence of muscle degradation to a very rare but severe muscle damage with acute kidney injury (rhabdomyolysis). Patients

carrying the SLC01B1 c.521C allele have a higher risk of simvastatin induced myopathy and rhabdomyolysis. The Clinical Pharmacogenetic Implementation Consortium (CPIC) highly recommends to adjust simvastatin dose according to the SLC01B1 c.521T>C genotype.

The *SLC01B1* gene codes for the solute carrier organic anion transporter family member 1B1 protein and affects the uptake and metabolism of statins in the liver. The risk for simvastatin-related myopathy is dose-dependent and 4 times higher in patients carrying one c.521T>C allele and 17 times higher in homozygous patients (CC).

ViennaLab RealFast™ Assays

- Fast and easy handling
- Less than 90 min from DNA to result
- Ready-to-use reagents
- Include controls for wild type and mutant genotype
- Compatible with various real-time PCR instruments
- Available in different pack sizes (100 reactions and 32 reactions)

REF:

SLC01B1 c.521T>C RealFast™ Assay: 7-210 (100 reactions)

SLC01B1 c.521T>C RealFast™ Assay: 7-213 (32 reactions)

For more details please visit: www.viennalab.com

ViennaLab RealFast™ Assays for single marker detection (compatible with the D2PCR™ Buffer)				
Area	Product	REF 100 / 32 Rxn	Label	Application
Carbamazepine Hypersensitivity	HLA-A3101 RealFast™ Assay	7-640 / 7-643	CE/IVD	Detects the human leukocyte antigen-A (HLA-A) 3101 allele, which is strongly associated with carbamazepine hypersensitivity reactions in Europeans and Japanese
	HLA-B1502 RealFast™ Assay	7-630 / 7-633	CE/IVD	Detects the human leukocyte antigen-B (HLA-B) 1502 allele, which is strongly associated with carbamazepine hypersensitivity reactions in Asian populations
Carbohydrate Intolerance	LCT -13910C>T RealFast™ Assay	7-150 / 7-153	CE/IVD	Detects the most common polymorphism in the <i>lactase (LCT)</i> gene causing lactase non-persistence
Cardiovascular Diseases (CVD)	FGB -455G>A RealFast™ Assay	7-230 / 7-233	CE/IVD	Identifies homozygosity for the -455G>A <i>fibrinogen beta-chain (FGB)</i> allele which may increase susceptibility to atherothrombosis in at-risk patients
	FV Leiden RealFast™ Assay	7-110 / 7-113	CE/IVD	Detects the most common genetic risk factor associated with venous thromboembolism, the 1691G>A mutation in the <i>Factor V (FV)</i> gene
	FXII 46C>T RealFast™ Assay	7-240 / 7-243	CE/IVD	Identifies patients with the unfavorable TT genotype for <i>Factor XII (FXII)</i> , who may have an increased susceptibility to thrombotic disorders
	FXIII V34L RealFast™ Assay	7-250 / 7-253	CE/IVD	Identifies carriers of the protective 34L variant of Factor XIII (FXIII) among at-risk patients of hereditary thrombophilia
	MTHFR 677C>T RealFast™ Assay	7-160 / 7-163	CE/IVD	Detect common mutations in the <i>methylenetetrahydrofolate reductase (MTHFR)</i> gene causing hyperhomocysteinemia, which is a risk factor for cardiovascular disease
	MTHFR 1298A>C RealFast™ Assay	7-170 / 7-173	CE/IVD	
	PAI-1 4G/5G RealFast™ Assay	7-180 / 7-183	CE/IVD	Detects the 4G risk allele in the <i>plasminogen activator inhibitor-1 (PAI-1)</i> gene, associated with cardiovascular disease and pregnancy complications
	PTH 20210G>A RealFast™ Assay	7-120 / 7-123	CE/IVD	Detects the second most important genetic risk factor for venous thromboembolism in the <i>prothrombin (PTH)</i> gene
Genetic Predisposition	HLA-B27 RealFast™ Assay	7-620 / 7-623	CE/IVD	Detects the human leukocyte antigen-B (HLA-B) 27 allele, which is associated with ankylosing spondylitis
Haemochromatosis	HFE C282Y RealFast™ Assay	7-130 / 7-133	CE/IVD	Detect common mutations in the <i>HFE</i> gene causing hereditary haemochromatosis (HH) type 1
	HFE H63D RealFast™ Assay	7-140 / 7-143	CE/IVD	
Pharmacogenetics	HLA-B5701 RealFast™ Assay	7-610 / 7-613	CE/IVD	Detects human leukocyte antigen-B (HLA-B) 5701 allele, which is associated with hypersensitivity to the anti-HIV drug abacavir
	IL28B RealFast™ Assay	7-200 / 7-203	CE/IVD	Detects a dinucleotide frame-shift variant coding for interleukin 28B (IL28B) and helps to predict the therapeutic response in Hepatitis C Virus infected patients
	SLC01B1c.521T>C RealFast™ Assay	7-210 / 7-213	CE/IVD	Detects a variant in human <i>solute carrier organic anion transporter family member 1B1 (SLC01B1)</i> gene in patients who are at higher risk for developing statin-induced myopathy
	VKORC1 -1639G>A RealFast™ Assay	7-190 / 7-193	CE/IVD	Detects the most important polymorphism in the <i>Vitamin K Epoxide Reductase Complex 1 (VKORC1)</i> gene associated with interindividual dose requirements for oral anticoagulants
ViennaLab RealFast™ Assays for multiplex testing - save costs and sample material (compatible with the D2PCR™ Buffer)				
Cardiovascular Diseases (CVD)	FV-PTH mpx RealFast™ Assay	7-115 / 7-118	CE/IVD	Simultaneous detection of the most important thrombophilic mutations 1691G>A in the <i>Factor V</i> gene and 20210G>A in the <i>prothrombin</i> gene
	MTHFR mpx RealFast™ Assay	7-165 / 7-168	CE/IVD	Simultaneous detection of the most common two mutations in the <i>MTHFR</i> gene: 677C>T and 1298A>C
COPD/ AAT deficiency	AAT mpx *) RealFast™ Assay	7-265 / 7-268	CE/IVD	Detects *S and *Z variants of the <i>SERPINA1</i> gene predisposing individuals to chronic obstructive pulmonary disease (COPD) and liver disease due to deficiency of alpha-1 antitrypsin (AAT)
Haemochromatosis	HFE mpx RealFast™ Assay	7-135 / 7-138	CE/IVD	Simultaneous detection of the two most common mutations in the <i>HFE</i> gene: H63D and C282Y
Pharmacogenetics	CYP2C9 mpx *) RealFast™ Assay	7-225 / 7-228	CE/IVD	Simultaneous detection of <i>CYP2C9</i> *2 (c.430C>T) and <i>CYP2C9</i> *3 (c.1075A>C) polymorphisms to determine the drug response of known targets, like S-warfarin or phenytoin

*) not suitable for ultrafast cycling on the MIC qPCR Cycler

Additional diagnostic applications that are covered by ViennaLab RealFast™ Assays: Liquid Profiling, Congenital Adrenal Hyperplasia, CYP2D6 CNV determination ^{NEW!}, Covid-19 testing ^{NEW!}.



Manufacturer:

ViennaLab Diagnostics GmbH

Gaudenzdorfer Guertel 43-45

A-1120 Vienna, Austria

www.viennalab.com

t: (+43-1) 8120156-0

e: info@viennalab.com



More details available at www.viennalab.com

Supplied by:



Tel: +44 (0)1235 431390

sales@oxfordbiosystems.com

www.oxfordbiosystems.com